JP2004501190A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501190A5
JP2004501190A5 JP2002504995A JP2002504995A JP2004501190A5 JP 2004501190 A5 JP2004501190 A5 JP 2004501190A5 JP 2002504995 A JP2002504995 A JP 2002504995A JP 2002504995 A JP2002504995 A JP 2002504995A JP 2004501190 A5 JP2004501190 A5 JP 2004501190A5
Authority
JP
Japan
Prior art keywords
dosage form
therapeutic agent
gastric
pharmaceutical dosage
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002504995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/020134 external-priority patent/WO2002000213A1/en
Publication of JP2004501190A publication Critical patent/JP2004501190A/ja
Publication of JP2004501190A5 publication Critical patent/JP2004501190A5/ja
Pending legal-status Critical Current

Links

JP2002504995A 2000-06-23 2001-06-22 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 Pending JP2004501190A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (2)

Publication Number Publication Date
JP2004501190A JP2004501190A (ja) 2004-01-15
JP2004501190A5 true JP2004501190A5 (enExample) 2005-02-17

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002504995A Pending JP2004501190A (ja) 2000-06-23 2001-06-22 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形

Country Status (11)

Country Link
EP (1) EP1305021A4 (enExample)
JP (1) JP2004501190A (enExample)
KR (1) KR20030013460A (enExample)
AU (2) AU2001268722B8 (enExample)
CA (1) CA2412490A1 (enExample)
CZ (1) CZ2003199A3 (enExample)
EA (1) EA200300046A1 (enExample)
HU (1) HUP0301465A3 (enExample)
IL (1) IL153497A0 (enExample)
MX (1) MXPA02012793A (enExample)
WO (1) WO2002000213A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2003015745A1 (en) * 2001-08-16 2003-02-27 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Expandable gastric retention device
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
ATE347358T1 (de) * 2003-04-17 2006-12-15 Jallal Messadek Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
CN101180073A (zh) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 胰岛素组合
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
DE102007026037A1 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
KR101687781B1 (ko) 2008-08-15 2016-12-20 데포메드 인코퍼레이티드 Ｃｎｓ 장애의 치료 및 예방을 위한 위 체류성 약학적 조성물
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
EP2661262B1 (en) * 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (zh) * 2012-05-07 2017-06-23 新疆医科大学 复方左旋多巴微囊漂浮片
CN104334123B (zh) 2012-06-07 2019-02-12 意比图密医疗有限公司 膨胀装置
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (ja) * 2013-04-22 2017-09-27 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
PL3054929T3 (pl) 2013-10-07 2021-05-31 Impax Laboratories, Llc Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania
BR112016012615B1 (pt) 2013-12-05 2023-02-07 Epitomee Medical Ltd Sistemas, e kit
JP2018506590A (ja) * 2015-02-27 2018-03-08 シンギュレイト・セラピューティクス・リミテッド・ライアビリティ・カンパニーＣｉｎｇｕｌａｔｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＬＬＣ トリパルス放出型賦活薬製剤
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
DK3648747T3 (da) 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP3970701B1 (en) 2018-06-27 2025-05-07 Amneal Complex Products Research LLC Self-regulating osmotic gastroretentive drug delivery systems
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
CA3139217A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US20220241222A1 (en) * 2019-06-26 2022-08-04 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
JP7624750B2 (ja) * 2020-03-02 2025-01-31 クラフト ヘルス プライベート リミテッド 持続的薬物放出のための経口剤形
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
EP1003483A1 (en) * 1997-07-23 2000-05-31 Perio Products Ltd Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Similar Documents

Publication Publication Date Title
AU2001268722B8 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
Prinderre et al. Advances in gastro retentive drug-delivery systems
JP6062465B2 (ja) カルビドパ／レボドパ胃内滞留性薬物供給
Nikam et al. Eudragit a versatile polymer: a review
Shashank et al. Approaches to increase the gastric residence time: floating drug delivery systems-a review
JP2008519070A5 (enExample)
AU2001268722A1 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
JP2006505566A5 (enExample)
JP2005508358A5 (enExample)
JP2012518655A5 (enExample)
PL129290B1 (en) Method of obtaining new forms of dipyridamole exhibiting prolonged action
JPH09316005A (ja) 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤
JP2004501186A (ja) アレンドロン酸塩及び／又はその他のビスホスホン酸塩の遅延型胃内放出のための組成物及び製剤
JP2000508673A (ja) イバンドロネートを含む経口薬理製剤
FR2830447A1 (fr) Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
PL207776B1 (pl) Kompozycja farmaceutyczna o zmodyfikowanym uwalnianiu
JP2011500553A (ja) ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
JP2005528430A5 (enExample)
CN101808665A (zh) 阿利吉仑和缬沙坦的药物组合
CN113476421B (zh) 一种非布司他的控释组合物及其制备方法
JP2008519069A5 (enExample)
CN101636153A (zh) 时间特异性延迟/脉冲释放剂型
CN101146521A (zh) 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
Hooda Gastroretentive drug delivery systems: A review of formulation approaches